Depression in patients with schizophrenia is common. Several factors was found to be associated with depression including medical illness, quality of life, positive symptoms, and typical antipsychotics. The Calgary depression scale of schizophrenia (CDSS) is commonly used for screening depression in schizophrenia,however; the Thai version of CDSS has not been validated. This study aims to a.) test the reliability and validity of the Thai version of Calgary depression scale of schizophrenia (CDSS) and b.) identify the prevalence and factors associated with depression in patients with schizophrenia including quality of life, type of antipsychotic drugs, and severity of schizophrenia in 60 patients with schizophrenia at the Faculty of Medicine, Chiang Mai University, Thailand.
Measurements: The Thai version of Calgary depression scale of schizophrenia (CDSS), Positive and Negative Syndrome Scale (PANSS), Hamilton Rating Scale for Depression-17 (HAM-D 17), Montgomery-Asberg Depression Rating Scale (MADRS), the Thai abbreviated version of World Health Organization quality of life (WHOQOL-BREF-THAI).
Study Type
OBSERVATIONAL
Enrollment
60
Chiang Mai University
Chiang Mai, Chiang Mai, Thailand
The reliability of the Thai version of the Calgary Depression Scale for Schizophrenia (CDSS) in schizophrenia patients.
The inter-rater reliability, the test-retest reliability will be analyzed.
Time frame: 3 months
The validity of the Thai version of the Calgary Depression Scale for Schizophrenia (CDSS) in schizophrenia patients.
The Positive and Negative Syndrome Scale (PANSS), Hamilton Rating Scale for Depression-17 (HAM-D 17), Montgomery-Åsberg Depression Rating Scale (MADRS) will be administered by the first rater, whereas the CDSS will be assessed by a second independent rater.
Time frame: 3 months
The prevalence of depression in patients with schizophrenia
The point prevalence of depression in patients with schizophrenia will be presented in percentage.
Time frame: 3 months
The association between depression in schizophrenia and quality of life.
The association between depression in schizophrenia and quality of life (WHOQOL-BREF-THAI).
Time frame: 3 months
The association between depression in schizophrenia and type of antipsychotic drugs.
The association between depression in schizophrenia and type of antipsychotic drugs (typical vs atypical).
Time frame: 3 months
The association between depression in schizophrenia and severity of schizophrenia.
The association between depression in schizophrenia and severity of schizophrenia (PANSS score).
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.